Plus Therapeutics Announces Promising Results from ReSPECT-GBM Phase 1/2 Glioblastoma Trial

Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for central nervous system (CNS) cancers, provided an update on its ongoing ReSPECT-GBM Phase 1/2 clinical trial. The trial is evaluating the company’s lead candidate, Rhenium (186Re) Obisbemeda, for the treatment of recurrent glioblastoma. The data were presented at the 2024 Congress of Neurological Surgeons (CNS) Annual Meeting, held on September 30, 2024, in Houston, Texas.

The presentation, titled “Treatment of Recurrent Glioblastoma (rGBM) via Convection Enhanced Delivery (CED) with Rhenium (186Re) Obisbemeda (Rhenium-186 Nanoliposome, 186RNL): ReSPECT-GBM Phase 1/2 Trial Update,” was delivered by lead investigator Dr. John Floyd, Associate Professor and Chair of Neurosurgery at the University of Texas Health Science Center San Antonio. The data demonstrated a favorable safety profile and promising efficacy results for Rhenium (186Re) Obisbemeda in patients with recurrent glioblastoma, a condition with a typically poor prognosis.

Dr. Floyd highlighted that the trial continues to show positive safety signals and potential efficacy, particularly with regard to survival rates. He emphasized that the results support further development of Rhenium (186Re) Obisbemeda as a potential treatment for this aggressive cancer. The trial is currently enrolling patients in the Phase 2 study. ReSPECT-GBM is an open-label, first-in-human Phase 1/2 study exploring the feasibility, dose escalation, and convection enhanced delivery (CED) parameters to establish the maximum tolerated dose (MTD), maximum feasible dose (MFD), safety, and potential efficacy of Rhenium (186Re) Obisbemeda in recurrent adult glioma.